MedPath

A clinical trial comparing the diagnostic yield of EBUS-TBNA using different number of needle passes through the mediastinal lymph nodes in patients having mediastinal lymphadenopathy.

Not Applicable
Conditions
Health Condition 1: J985- Diseases of mediastinum, not elsewhere classified
Registration Number
CTRI/2023/02/049627
Lead Sponsor
Randeep Singh
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Consenting subjects between 18 and 75 years of age.

2.Subjects with mediastinal lymphadenopathy scheduled for EBUS-TBNA as part of clinical care.

3.Enlarged ( >10 mm in short axis) intrathoracic lymph nodes seen on computed tomography (CT) /PET CT of the chest.

Exclusion Criteria

1.Contra-indications to EBUS(coagulopathy, anticoagulation, thrombocytopenia, other bleeding diatheses).

2.Pregnant females.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare the diagnostic yield of EBUS-TBNA using different numbers of lymph node agitations (10-15 vs 15-20 vs 20-25) in patients with mediastinal lymphadenopathy.Timepoint: 8 week
Secondary Outcome Measures
NameTimeMethod
1.To compare the diagnostic yield of EBUS-TBNA using 10-15 versus 15-20 versus 20-25 lymph node agitations in patients with malignant mediastinal lymph node involvement. <br/ ><br> <br/ ><br>2.To estimate the rate of adverse events (bleeding, pneumothorax, hypoxemia, mediastinitis) in patients of mediastinal lymphadenopathy undergoing different number of agitations (10-15 vs 15-20 vs 20-25) per lymph node pass. <br/ ><br> <br/ ><br>3.To compare the specimen adequacy using different numbers of agitations (10-15 vs 15-20 vs 20-25) for immunohistochemical/molecular analysis. <br/ ><br>Timepoint: 8 week
© Copyright 2025. All Rights Reserved by MedPath